Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide and Oral THU-Decitabine in High Risk Sickle Cell Disease
NCT04055818Phase 1Recruiting
- Sponsor
- EpiDestiny
- Start
- Jan 2020
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in sickle cell disease (SCD) comparing Nicotinamide -> Combination with THU Decitabine -> Combination (2 arms). Primary endpoint: Blood Hemoglobin at 12 weeks. Started Jan 2020; status: recruiting.
02
Drugs
nicotinamidetetrahydrouridinedecitabine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04055818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04055818.